API

Desvenlafaxine (100mg)

Drug classification

Antidepressant; serotonin-norepinephrine reuptake inhibitor (SNRI).

Dosage form

Film-coated oral tablet containing 100 mg desvenlafaxine.

API strength per dosage

Dose

Desvenlafaxine is typically initiated at 50 mg once daily for adults; 100 mg daily is the maximum recommended dose. Not approved for pediatric use. In moderate to severe renal or hepatic impairment, dose adjustment or lower maximum doses are advised. Always individualize dosing and consult product information for specific recommendations.

Mechanism of action

Desvenlafaxine inhibits the reuptake of serotonin and norepinephrine by blocking the serotonin transporter (SERT) and norepinephrine transporter (NET) in the central nervous system, increasing synaptic concentrations of these neurotransmitters, which enhances mood and alleviates depressive symptoms.

Indications

Depression

Side effects

Anxiety Constipation Decreased appetite Dizziness Increased sweating Insomnia difficulty in sleeping Nausea Sexual dysfunction Vomiting

Pregnancy category

Desvenlafaxine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; consult healthcare provider.

Precautions

Monitor for suicidal thoughts, blood pressure, serotonin syndrome, hyponatremia, bleeding risk, glaucoma, seizure history, renal/hepatic impairment, discontinuation symptoms, bipolar disorder activation, and drug interactions; use caution in pregnancy and lactation; avoid abrupt cessation; assess for allergy to desvenlafaxine or venlafaxine.

Contraindications

Hypersensitivity to desvenlafaxine, venlafaxine, or any excipients, concomitant use with MAO inhibitors or within 7 days of discontinuing MAO inhibitors, uncontrolled narrow-angle glaucoma, severe hepatic impairment.